XIAP-associated factor 1 interacts with and attenuates the trans-activity of four and a Half LIM protein 2

Molecular Carcinogenesis

Volumn 50, Issue 3, 2011, Pages 199-207

  Zhang, Wenjing ^a,b   Yang, Yi ^b   Jiang, Bo ^a   Peng, Junzhong ^b   Tu, Shuiping ^b   Sardet, Claude ^c   Zhang, Yusheng ^a,b   Pang, Roberta ^b   Hung, Ivan F ^b   Tan, V P Y ^b   Lam, Colin S C ^b   Wang, Jide ^a,b   Wong, Benjamin C Y ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIV MONTPELLIER   (France)

Author keywords

FHL2; Gastric cancer; XAF1

Indexed keywords

BETA CATENIN; BINDING PROTEIN; LIM PROTEIN; LIM PROTEIN 2; TRANSCRIPTION FACTOR AP 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; XIAP ASSOCIATED FACTOR 1;

ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; CYTOPLASM; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STOMACH CANCER;

BETA CATENIN; BLOTTING, WESTERN; CELL NUCLEUS; CYTOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUCIFERASES; MITOCHONDRIA; MUSCLE PROTEINS; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 79951816405     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20705     Document Type: Article

References (35)

1. Liston P, Fong WG, Kelly NL, et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol 2001; 3: 128-133.
2. Byun DS, Cho K, Ryu BK, et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 2003; 63: 7068-7075.
3. Zou B, Chim CS, Zeng H, et al. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology 2006; 131: 1835-1843.
4. Wang J, Gu Q, Li M, et al. Identification of XAF1 as a novel cell cycle regulator through modulating G2/M checkpoint and interaction with checkpoint kinase 1 in gastrointestinal cancer. Carcinogenesis 2009; 30: 1507-1516.
5. Leaman DW, Chawla-Sarkar M, Vyas K, et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem 2002; 277: 28504-28511.
6. Chung SK, Lee MG, Ryu BK, et al. Frequent alteration of XAF1 in human colorectal cancers: Implication for tumor cell resistance to apoptotic stresses. Gastroenterology 2007; 132: 2459-2477.
7. Wang J, Peng Y, Sun YW, et al. All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer. Gastroenterology 2006; 130: 747-758.
8. Siegelin M, Touzani O, Toutain J, Liston P, Rami A. Induction and redistribution of XAF1, a new antagonist of XIAP in the rat brain after transient focal ischemia. Neurobiol Dis 2005; 20: 509-518.
9. Straszewski-Chavez SL, Visintin IP, Karassina N, et al. XAF1 mediates tumor necrosis factor-alpha-induced apoptosis and X-linked inhibitor of apoptosis cleavage by acting through the mitochondrial pathway. J Biol Chem 2007; 282: 13059-13072.
10. Genini M, Schwalbe P, Scholl FA, Remppis A, Mattei MG, Schafer BW. Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. DNA Cell Biol 1997; 16: 433-442.
11. Johannessen M, Møller S, Hansen T, Moens U, Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 2006; 63: 268-284.
12. Kadrmas JL, Beckerle MC. The LIM domain: From the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol 2004; 5: 920-931.
13. Retaux S, Bachy I. A short history of LIM domains (1993-2002): From protein interaction to degradation. Mol Neurobiol 2002; 26: 269-281.
14. Wang J, Yang Y, Xia HH, et al. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 2007; 132: 1066-1076.
15. Li M, Wang J, Ng SS, et al. The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities. Glia 2008; 56: 1328-1338.
16. Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341-11347.
17. Gabriel B, Fischer DC, Orlowska-Volk M, et al. Expression of the transcriptional coregulator FHL2 in human breast cancer: A clinicopathologic study. J Soc Gynecol Investig 2006; 13: 69-75.
18. Sanchez-Garcia I, Rabbitts TH. LIM domain proteins in leukaemia and development. Semin Cancer Biol 1993; 4: 349-358.
19. Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin. Mol Cell Biol 2004; 24: 10689-10702.
20. Morlon A, Sassone-Corsi P. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc Natl Acad Sci USA 2003; 100: 3977-3982.
21. Zhang W, Jiang B, Guo Z, et al. Four and a half LIM protein 2 (FHL2) promotes invasive potential and epithelial-mesenchymal transition in colon cancer. Carcinogenesis 2010; 31: 1220-1229.
22. Li HY, Ng EK, Lee SM, et al. Protein-protein interaction of FHL3 with FHL2 and visualization of their interaction by green fluorescent proteins (GFP) two-fusion fluorescence resonance energy transfer (FRET). J Cell Biochem 2001; 80: 293-303.
23. Yu LF, Wang J, Zou B, et al. XAF1 mediates apoptosis through an extracellular signal-regulated kinase pathway in colon cancer. Cancer 2007; 109: 1996-2003.
24. Paul C, Lacroix M, Iankova I, et al. The LIM-only protein FHL2 is a negative regulator of E4F1. Oncogene 2006; 25: 5475-5484.
25. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275: 1784-1787.
26. Qiao L, Wang Y, Pang R, et al. Oncogene functions of FHL2 are independent from NF-kappaBIalpha in gastrointestinal cancer. Pathol Oncol Res 2009; 15: 31-36.
27. Chan KK, Tsui SK, Lee SM, et al. Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene 1998; 210: 345-350.
28. Wei Y, Renard CA, Labalette C, et al. Identification of the LIM protein FHL2 as a coactivator of beta-catenin. J Biol Chem 2003; 278: 5188-5194.
29. Lévy L, Neuveut C, Renard CA, et al. Transcriptional activation of interleukin-8 by beta-catenin-Tcf4. J Biol Chem 2002; 277: 42386-42393.
30. Tu SP, Liston P, Cui JT, et al. Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer. Int J Cancer 2009; 125: 688-697.
31. Corbi N, Libri V, Onori A, Passananti C. Synthetic zinc finger peptides: Old and novel applications. Biochem Cell Biol 2004; 82: 428-436.
32. Fimia GM, De Cesare D, Sassone-Corsi P. A family of LIM-only transcriptional coactivators: Tissue-specific expression and selective activation of CREB and CREM. Mol Cell Biol 2000; 20: 8613-8622.
33. Sun Y, Qiao L, Zou B, et al. Interactions between XIAP associated factor 1 and a nuclear co-activator, CBP, in colon cancer cells. Digestion 2008; 77: 79-86.
34. Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 2007; 282: 26202-26209.
35. Li D, Wang Z, Yan J, et al. Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J Clin Invest 2009; 119: 349-361.